Clinical Trial Update: Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase II study evaluating short-term cultured autologous anti-tumor lymphocytes after lymphocyte-depleting chemotherapy in metastatic melanoma; results were pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Autologous anti-tumor lymphocytes (tumor-reactive autologous lymphocytes)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Melanoma, Malignant Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2013-05-27